Palvella Therapeutics Inc

PVLA is in a Stage 2 advancing structure with rising EMAs and a dominant Higher Highs & Higher Lows pattern indicating persistent demand. The medium-term bias is bullish, and the current pullback into the rising 9- and 20-EMA zone offers a favorable speculative entry. Maintaining discipline around this support area aligns with trend momentum, while a decisive break below EMAs would invalidate the bullish posture.

• ↑Phase III SELVA trial delivered 95% patient response for Cuturin Rapamycin.
• ↑Addressable market of 30,000 U.S. patients implies multibillion-dollar potential.
• ↓Negative profitability metrics and high leverage indicate financial strain.